Symbols

BLLN

BillionToOne·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BLLN

Billiontoone, Inc.

A high-growth U.S.molecular diagnostics company,specializing in single-base-pair precision DNA detection technology,primarily focused on non-invasive prenatal testing and cancer liquid biopsy products

Industry

Biological Technology

Established Date

Listing Date

11/06/2025

Exchange

NASDAQ Stock Exchange

Full-time Employees

620

Fiscal Year Ends

12-31

Website

www.billiontoone.com

Security Type

Common stock

Office address

1035 O’Brien Drive Menlo Park CA 94025

Business

Introduction

BillionToOne, Inc., began operations as a Delaware corporation in 2016. The company has developed a revolutionary single-molecule NGS platform capable of detecting and precisely quantifying gene targets with single-molecule sensitivity. The company's technology platform enables it to create industry-leading prenatal and oncology products.

Company Financials

EPS

BLLN has released its 2025 Q3 earnings. EPS was reported at 0.1, versus the expected 0.16, missing expectations. The chart below visualizes how BLLN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BLLN has released its 2025 Q3 earnings report, with revenue of 83.52M, reflecting a YoY change of 117.40%, and net profit of 5.71M, showing a YoY change of 138.32%. The Sankey diagram below clearly presents BLLN's revenue sources and cost distribution.